RT Journal Article
SR Electronic
T1 Serum Contactin-1 in CIDP
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e1040
DO 10.1212/NXI.0000000000001040
VO 8
IS 5
A1 Luuk Wieske
A1 Lorena Martín-Aguilar
A1 Janev Fehmi
A1 Cinta Lleixà
A1 Marleen J.A. Koel-Simmelink
A1 Madhurima Chatterjee
A1 Zoë van Lierop
A1 Joep Killestein
A1 Camiel Verhamme
A1 Luis Querol
A1 Simon Rinaldi
A1 Charlotte E. Teunissen
A1 Filip Eftimov
YR 2021
UL http://nn.neurology.org/content/8/5/e1040.abstract
AB Objective To investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region.Methods Serum contactin-1 levels were measured in 187 patients with CIDP and 222 healthy controls. Paranodal antibodies were investigated in all patients.Results Serum contactin-1 levels were lower in patients (N = 41) with paranodal antibodies compared with patients (N = 146) without paranodal antibodies (p < 0.01) and showed good discrimination between these groups (area under the curve 0.84; 95% CI: 0.76–0.93).Conclusions These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP.Classification of Evidence This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%–85%) and a specificity of 97% (95% CI: 83%–100%).AUC=area under the curve; CNTN1=contactin-1; IVIg=IV immunoglobulin; ROC=receiver operating characteristic; sCNTN1=serum levels of contactin-1